BioCentury | Feb 18, 2008
Company News

Intracel, Vaccinogen deal

...Vaccinogen acquired all assets related to Intracel’s OncoVax . The autologous tumor cells combined with bacille...
...in the U.S., where it is in Phase III testing. Financial terms were not disclosed. Intracel Holdings...
BioCentury | Apr 30, 2007
Company News

Intracel, OxiGene deal

...to treat an undisclosed indication by the end of 2009. Further terms were not disclosed. Intracel Holdings...
BioCentury | Jul 24, 2006
Clinical News

OncoVax: Phase III started

...and European Phase III trial in 560 patients who have had their tumors surgically removed. Intracel Holdings...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

...from MUC-1 Non-small cell lung cancer (NSCLC) Ph IIb compl (start Ph III in mid-06) Intracel...
BioCentury | May 1, 2006
Clinical News

OncoVax: Phase III start

...and European Phase III trial in 560 patients who have had their tumors surgically removed. Intracel Holdings...
BioCentury | May 2, 2005
Finance

MPM's portfolio

...6/14/04 $27.0 Luke Evnin Intercell (VSE:ICLL) Cancer; Infectious Austria Series C 11/21/03 $50.0 Luke Evnin Intracel...
BioCentury | Jul 2, 2001
Strategy

KSB's antibody strategy

...to three human MAbs with potential in cancer from Human Antibody Sciences, a subsidiary of Intracel...
...a radiolabeled MAb in Phase I trials for ovarian cancer following surgery and chemotherapy. "The Intracel...
BioCentury | Jun 25, 2001
Company News

Avicenna Inc., Intracel Corp., KS Biomedix deal

...cancers. Separately, KSB acquired an exclusive license to three human MAbs to treat cancer from Intracel...
...in Phase I trials for ovarian cancer following surgery and chemotherapy. Avicenna Inc., Edmonton, Alberta Intracel...
BioCentury | Jun 19, 2001
Company News

KSB acquiring Avicenna

...to three human MAbs with potential in cancer from Human Antibody Sciences, a subsidiary of Intracel...
BioCentury | Jan 2, 2001
Company News

Intracel Corp., Trinity deal

...TRIB will acquire Intracel's Bartels Inc. diagnostics division (Issaquah, Wash.) for $9.3 million, including $3.2 million...
...syncytial virus diagnostic kits and U.S. sales force, will be immediately accretive to TRIB's earnings. Intracel...
Items per page:
1 - 10 of 29
BioCentury | Feb 18, 2008
Company News

Intracel, Vaccinogen deal

...Vaccinogen acquired all assets related to Intracel’s OncoVax . The autologous tumor cells combined with bacille...
...in the U.S., where it is in Phase III testing. Financial terms were not disclosed. Intracel Holdings...
BioCentury | Apr 30, 2007
Company News

Intracel, OxiGene deal

...to treat an undisclosed indication by the end of 2009. Further terms were not disclosed. Intracel Holdings...
BioCentury | Jul 24, 2006
Clinical News

OncoVax: Phase III started

...and European Phase III trial in 560 patients who have had their tumors surgically removed. Intracel Holdings...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

...from MUC-1 Non-small cell lung cancer (NSCLC) Ph IIb compl (start Ph III in mid-06) Intracel...
BioCentury | May 1, 2006
Clinical News

OncoVax: Phase III start

...and European Phase III trial in 560 patients who have had their tumors surgically removed. Intracel Holdings...
BioCentury | May 2, 2005
Finance

MPM's portfolio

...6/14/04 $27.0 Luke Evnin Intercell (VSE:ICLL) Cancer; Infectious Austria Series C 11/21/03 $50.0 Luke Evnin Intracel...
BioCentury | Jul 2, 2001
Strategy

KSB's antibody strategy

...to three human MAbs with potential in cancer from Human Antibody Sciences, a subsidiary of Intracel...
...a radiolabeled MAb in Phase I trials for ovarian cancer following surgery and chemotherapy. "The Intracel...
BioCentury | Jun 25, 2001
Company News

Avicenna Inc., Intracel Corp., KS Biomedix deal

...cancers. Separately, KSB acquired an exclusive license to three human MAbs to treat cancer from Intracel...
...in Phase I trials for ovarian cancer following surgery and chemotherapy. Avicenna Inc., Edmonton, Alberta Intracel...
BioCentury | Jun 19, 2001
Company News

KSB acquiring Avicenna

...to three human MAbs with potential in cancer from Human Antibody Sciences, a subsidiary of Intracel...
BioCentury | Jan 2, 2001
Company News

Intracel Corp., Trinity deal

...TRIB will acquire Intracel's Bartels Inc. diagnostics division (Issaquah, Wash.) for $9.3 million, including $3.2 million...
...syncytial virus diagnostic kits and U.S. sales force, will be immediately accretive to TRIB's earnings. Intracel...
Items per page:
1 - 10 of 29